€ 20.99 · 4.7 (548) · In Magazzino
New therapy with unique bacterial strain B. bifidum HI-MIMBb75 promises help for approximately 80 million Europeans suffering from irritable bowel syndrome1 - World's largest clinical OTC irritable bowel syndrome trial investigating the efficacy of this particular strain published in the renowned medical journal The Lancet Gastroenterology & Hepatology2 - Results show significant efficacy for all predominant irritable bowel syndrome symptoms and all subtypes while simultaneously improving patients’ quality of life2 (Gräfelfing/Munich, Germany) The world's largest OTC irritable bowel syndrome (IBS) trial comes up with remarkable results, which were recently published in the renowned medical journal The Lancet Gastroenterology & Hepatology. For the first time, leading German scientists around Prof. Dr. Peter Layer (Israelitic Hospital Hamburg) were able to prove the significant efficacy of a heat-inactivated bacterial strain on patients with IBS. Trial results show that B. bifidum HI-M
CPhI worldwide: German probiotics company SYNformulas seeks partnerships to drive
Irritable bowel syndrome - Wikipedia
Gut bless you: The microbiota-gut-brain axis in irritable bowel syndrome
The Microbiota-Gut-Brain Axis
Frontiers The Microbiome and Irritable Bowel Syndrome – A Review on the Pathophysiology, Current Research and Future Therapy
Gastrointestinal Disorders, Free Full-Text
PDF) Review article: Linaclotide for the management of irritable bowel syndrome with constipation
Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice - Paul Moayyedi, Fermín Mearin, Fernando Azpiroz, Viola Andresen, Giovanni Barbara, Maura Corsetti, Anton Emmanuel, A Pali S Hungin, Peter
Irritable bowel syndrome Nature Reviews Disease Primers
Irritable bowel syndrome: a gut microbiota-related disorder? American Journal of Physiology-Gastrointestinal and Liver Physiology